MIRA Overview

U.S. Stock Market Update: U.S. stock futures rose slightly following President Trump's announcement of a trade deal with Vietnam, while the Nasdaq and NYSE will have early closures for Independence Day. The S&P 500 reached a record high, driven by gains in materials, technology, and energy sectors, despite a decline in private sector jobs reported by ADP.

Corporate Highlights: Notable stock movements included a 21% surge for Greenbrier Companies after strong earnings, while Franklin Covey dropped 7.82% due to disappointing results. Xponential Fitness saw an 18.63% increase after an SEC investigation concluded without action, and Global Interactive Technologies skyrocketed 223.31% amid significant corporate changes.

Datadog's S&P 500 Inclusion: Datadog Inc's shares rose 10.6% in pre-market trading after the announcement of its inclusion in the S&P 500 index, effective July 9, 2025, replacing Juniper Networks.

Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with Global Interactive Technologies surging 217.7% and Fly-E Group tumbling 25.8% following a reverse stock split announcement.

MIRA Pharmaceuticals Stock Surge: MIRA Pharmaceuticals' stock price jumped approximately 50.8% to $1.87 after the announcement of Mira-55, a synthetic marijuana analog that provides pain relief comparable to morphine without psychoactive effects.

Regulatory Advancements and Future Prospects: The DEA confirmed that Mira-55 is not a controlled substance, facilitating its clinical development, while the company also progresses with other pain management therapies and an acquisition aimed at enhancing its market position.

MIRA Pharmaceuticals' SKNY-1 Study Results: MIRA Pharmaceuticals announced promising results from animal studies of SKNY-1, a next-generation oral therapeutic aimed at addressing obesity and nicotine cravings, showing significant weight loss, appetite suppression, and reversal of nicotine-seeking behavior within six days of treatment.

Market Potential and Drug Development: With a focus on the $200 billion market for obesity and smoking-related health issues, MIRA plans to prioritize SKNY-1 as a key asset, especially as it seeks to complete its acquisition of SKNY Pharmaceuticals, while also highlighting the drug's advantages over existing GLP-1 injectables.

Mira Pharmaceuticals Acquisition: Mira Pharmaceuticals' Board approved the acquisition of SKNY Pharmaceuticals, with a combined enterprise value exceeding $60 million, following independent valuations that highlighted the strengths of both companies' pipelines.

Ketamir-2 Study Results: Mira released positive results from a neurotoxicity study of its drug Ketamir-2, confirming its safety profile and supporting further clinical development, while MIRA stock experienced a slight decline in premarket trading.